Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus VUSION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus VUSION.
ALTABAX vs VUSION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Antifungal; inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Apply a thin layer to the affected area twice daily (morning and evening) for 7 days. Topical use only.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life is approximately 36 hours, reflecting prolonged exposure in stratum corneum and hair follicles; systemic half-life is negligible due to minimal percutaneous absorption.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Primarily eliminated via biliary/fecal route; minimal renal excretion (<5% unchanged). Approximately 80% of the absorbed dose appears in feces as unchanged drug and metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic